Seema A Bhat, MD
Academic Title: Associate Professor in the College of Medicine
Research Program: Leukemia and Hematologic Malignancies
About Me
More info forI am a hematologist who specializes in treating patients with chronic lymphocytic leukemia (CLL). I was excited to join the OSUCCC – James because of the cutting-edge and exemplary work done by the Leukemia and Hematologic Malignancies program, which has transformed the treatment approach for patients with CLL, leading to the approval of more effective and innovative treatments for this disease. The James is leading the race to cure CLL, and I am honored to be a member of that team as a clinical investigator focusing on designing and leading clinical trials. I have served as a principal investigator on a number of clinical trials, and I also collaborate with laboratory scientists to develop novel therapies for CLL. My research interests include developing novel targeted therapies for the treatment of CLL with the goal of curing this disease without the need of chemotherapy. My aim is to improve the quality of life for these patients so that they can lead a normal and productive life without enduring the toxic effects of treatment. In addition to my clinical work, I am an assistant professor in the Department of Internal Medicine, Division of Hematology at The Ohio State University and have served on a number of national committees, including the NCCN Guidelines panels for cancer- and chemotherapy-induced anemia, chronic lymphocytic leukemia/small lymphocytic lymphoma and hairy cell leukemia. I feel privileged to be part of OSUCCC – The James. We believe in providing personalized care for each patient to ensure better outcomes, and it’s truly rewarding to contribute to this medical and academic community as we work toward our common goal of a cancer-free world.
Clinical Expertise
More info for- Hematology
- Chronic Lymphocytic Leukemias
- Lymphomas
Where I See Patients
More info forEducation & Training
More info forMedical School
- Government Medical College Srinagar
Kashmir University, India
Fellowship - Hematology & Oncology
- Roswell Park Cancer Institute
Elm And Carlton St, Buffalo, NY
Internship - Internal Medicine
- Sisters of Charity Hospital of Buffalo-GME
2157 Main St, Buffalo, NY
Residency - Internal Medicine
- Sisters of Charity Hospital of Buffalo-GME
2157 Main St, Buffalo, NY
- Government Medical College Srinagar
Academic Office & Contact Information
More info forAcademic Office:
The James Outpatient Care 7166
2121 Kenny Rd
Columbus, Ohio 43221Email:
bhat.82@osu.eduReviews
More info forPatient Satisfaction Review
The overall patient satisfaction rating is an average of all patient responses to the five questions gathered from the Outpatient Oncology survey, developed by Press Ganey Associates for use in oncology clinics across the country. On behalf of The James, Press Ganey administers the survey to patients who see our providers in an outpatient clinic office. For additional information about the patient satisfaction survey, please visit our
Patient Satisfaction Survey page The comments are submitted by patients and reflect their view and opinions. The comments are not endorsed by and do not necessarily reflect the views of The James.
Videos
More info forPublications
More info forOctober 1, 2024Incidence, description, and timing of serious and opportunistic infections in patients with hairy cell leukemia.
Kapoor N, Zhao Q, Stiff A, Bhat SA, Anghelina MI, Andritsos LA, Blachly JS, Epperla N, Boghdadly ZE, Grever MR, Rogers KA
EJHaem
August 17, 2024Atrial fibrillation burden and clinical outcomes following BTK inhibitor initiation.
Gambril JA, Ghazi SM, Sansoterra S, Ferdousi M, Kola-Kehinde O, Ruz P, Kittai AS, Rogers K, Grever M, Bhat S, Wiczer T, Byrd JC, Woyach J, Addison D
Leukemia
August 8, 2024LP-118 is a novel B-cell lymphoma 2 / extra-large inhibitor that demonstrates efficacy in models of venetoclax-resistant chronic lymphocytic leukemia.
Ravikrishnan J, Diaz-Rohena DY, Muhowski E, Mo X, Lai TH, Misra S, Williams CD, Sanchez J, Mitchell A, Satpati S, Perry E, Kaufman T, Liu C, Lozanski A, Lozanski G, Rogers K, Kittai AS, Bhat SA, Collins MC, Davids MS, Jain N, Wierda WG, Lapalombella R, Byrd JC, Tan F, Chen Y, Chen Y, Shen Y, Anthony SP, Woyach JA, Sampath D
Haematologica
June 8, 2024Hairy cell leukemia variant and WHO classification correspondence Re: 5th edition WHO classification haematolymphoid tumors: lymphoid neoplasms.
Grever M, Andritsos L, Anghelina M, Arons E, Banerji V, Barrientos J, Bhat SA, Blachly J, Broccoli A, Call T, Dearden C, Dietrich S, Else M, Epperla N, Fagarasanu A, Falini B, Forconi F, Gozzetti A, Hampel P, Hermel DJ, Iyengar S, Johnston JB, Juliusson G, Kreitman RJ, Lauria F, Lozanski G, Oakes CC, Parikh SA, Park J, Quest G, Rai K, Ravandi F, Robak T, Rogers KA, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam CS, Tiacci E, Troussard X, Wörmann B, Zent CS, Zenz T, Zinzani PL
Leukemia
March 29, 2024Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study.
Kittai AS, Bond D, Huang Y, Bhat SA, Blyth E, Byrd JC, Chavez JC, Davids MS, Dela Cruz JP, Dowling MR, Duffy C, Ho C, Jacobson C, Jaglowski S, Jain N, Lin KH, Miller C, McCarthy C, Omer Z, Parry E, Rai M, Rogers KA, Saha A, Schachter L, Scott H, Senapati J, Shadman M, Siddiqi T, Stephens DM, Vanguru V, Wierda W, Woyach JA, Thompson PA
J Clin Oncol
February 19, 2024Comparison of karyotype scoring guidelines for evaluating karyotype complexity in chronic lymphocytic leukemia.
Avenarius MR, Huang Y, Kittai AS, Bhat SA, Rogers KA, Grever MR, Woyach JA, Miller CR
Leukemia
February 15, 2024Racial disparities in chronic lymphocytic leukemia/small lymphocytic lymphoma accounting for small molecule inhibitors: A real-world cohort analysis.
Kittai AS, Hang Y, Bhat SA, Clark A, Grever M, Rhodes JM, Roberts M, Rogers KA, Teschemaker A, Munoz-Sagastibelza M, Woyach JA, Barrientos JC
Am J Hematol
November 6, 2023First in Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma.
Woyach JA, Stephens DM, Flinn IW, Bhat SA, Savage RE, Chai F, Eathiraj S, Reiff SD, Muhowski EM, Granlund L, Szuszkiewicz L, Wang W, Schwartz B, Ghori R, Farooqui MZH, Byrd JC
Cancer Discov
November 1, 2023Single-center study of outcomes of patients with hairy cell leukemia who contracted SARS-CoV-2.
Annunzio K, Ozga M, Huang Y, Anghelina M, Bhat SA, Blachly JS, Grever MR, Lozanski G, Neal J, Shindiapina P, Rogers KA
EJHaem
October 18, 2023Characteristics and Outcomes of Patients with CLL and CDKN2A/B Deletion by Fluorescence in situ Hybridization.
Teierle SM, Huang Y, Kittai AS, Bhat SA, Grever MR, Rogers KA, Zhao W, Jones D, Byrd JC, Avenarius MR, Heerema NA, Woyach JA, Miller CR
Blood Adv
February 2, 2023Cardiovascular Magnetic Resonance Imaging in Patients With Ibrutinib-Associated Cardiotoxicity.
Buck B, Chum AP, Patel M, Carter R, Nawaz H, Yildiz V, Ruz P, Wiczer T, Rogers KA, Awan FT, Bhat S, Guha A, Kittai AS, Simonetti OP, Raman SV, Wallace G, Sanchez R, Bonsu JM, Gambril J, Haddad D, Mann J, Wei L, Kola-Kehinde O, Byrd JC, Woyach JA, Addison D
JAMA Oncol
Consulting and Related Relationships
More info forAt The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 09/30/2024, Dr. Bhat has reported relationships with the companies or entities listed below. If you have questions about the relationships listed below, please ask the faculty member. If you have questions about how these relationships are monitored by The Ohio State University Wexner Medical Center, please contact our Compliance Office.
- AstraZeneca
- Pharmacyclics
- AbbVie
Patient Comments
Have always received excellent care at OSU. Very prompt replies on MyChart.
Dr Bhat was excellent and showed much compassion
I tell friends and family that if you are not going to do what the doctor tells you then why bother going. I have complete faith in Dr. Seems Bhatt and consider myself very fortunate to have her as my Hemotologist. The nurses and OSU students who support her are the best....I cannot give them higher praise.
All good
I'm not sure you can improve on time or the care being offered
Excellent appointment with short wait times.
Dr.Bhat is simply the best, as is Corrine, her nurse practitioner, that I see most visits. Takes all the time you need & answers every question thoroughly. Very caring & committed staff!
Dr. Bhat is excellent.
We just our team we have,THANK YOU JESUS FOR OUR TEAM
I feel so fortunate to live a mere 30 minutes from such a wonderful hospital!
Dr. Bhat always ask me about problems or concerns I may have.
My care provider spent much more time with me in this last visit asking more pertinent questions, going over my blood results, and providing information. In the past, the nurse practitioner did all of those things. This time, the nurse practitioner didn't see me at all and it was helpful because it took less time and there wasn't a duplication of information and questions.
Dr. Bhat is phenomenal.
Dr Bhat was very informative...feel comfortable with her
As much previously, my time spent in the exam room was much too long.
Once I was able to see the care team, everything was excellent. I appreciated the amount of time allowed for answering questions.
Dr Bhat very good
Dr. Bhat and the nurse practitioners have always answered my questions clearly in a way that I can understand.
Sometimes feel invalidated about symptoms
Always a very positive experience when I visit my oncologist!
Very good experience.
Dr. Both appeared to have more time to discuss my questions than in previous appointments.
Dr Bott's kindness , caring and professionalism was very much appreciated . The way she explained things and her compassion towards me is just what I needed. She is a great asset to OSU and a real treasure. I am grateful to be in her care .
Dr. Bhat and CNP were very attentive this visit. I felt that they truely cared about my concerns and health care. Many times in the past I did not feel that way when leaving the facility.
The doctor asks leading questions which she already knows the answers to because her staff has talked with me ahead of her visit and informed her. I find this disconcerting. It would be better if she were straight forward and say, "My staff told me you had a visit to the ER since I saw you last; would you tell me what happened? It would be a better, more honest approach.